Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $120.98, moving +1.78% from the previous trading session.

Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know

Amgen

Biogen

Gilead Sciences

Moderna

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The short interest data is out for November 30, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Which Big Biotechs Short Sellers Favor Now

Lovesac Company

NextEra Energy

Block

These innovative companies can make investors rich.

4 Game-Changing Stocks to Invest $1,000 In Right Now

Ingredion

Intel

Science Applications International

Tapestry

Polaris Capital Management leader Bernard Horn (Trades, Portfolio) released his third-quarter portfolio earlier this week.

Bernard Horn's Top 5 Buys of the 3rd Quarter

Intra-Cellular Therapies

These two biotech companies are safe bargains in today's volatile market.

2 Underrated Biotech Stocks to Buy Now

The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Big Biotech Short Sellers Seek Cover

Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.

Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval

BOSTON--(BUSINESS WIRE)--Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time

Altria

Walgreens

Western Digital

Value investors, get those shopping carts ready.

4 of the Cheapest Stocks to Buy Right Now

Mastercard

Netflix

These stocks can bring investors substantial returns for many years to come.

Got $10,000? Here Are 3 Game-Changing Stocks to Buy

Orchard Therapeutics plc - ADR

These companies are devoted to helping patients who don't have any other options.

Got $1,000? Invest in These 2 Rare Disease Stocks

Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Should Value Investors Consider Alexion (ALXN) Stock Now?

Fastly

Green Thumb Industries Inc.

Intuitive Surgical

Pinterest

Sirius XM Holdings Inc

Owning innovative companies with clear-cut competitive advantages is a recipe for wealth creation.

Got $10,000? 10 Stocks to Buy and Hold for 10 Years

Bayer AG

Sanofi

The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared first on Investor's Business Daily.

These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable

BOSTON--(BUSINESS WIRE)--Alexion to Present at Upcoming Virtual Investor Conferences

Alexion to Present at Upcoming Virtual Investor Conferences

Alexion Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Stock Upgrades: Alexion Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's Business Daily.

Stock Upgrades: Alexion Pharmaceuticals Shows Rising Relative Strength

BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition

Broadcom

Okta

A falling market represents the perfect opportunity to buy into these game-changing companies.

Got $1,000? 3 Explosive Stocks to Buy During a Market Crash

The biotech delivered strong top- and bottom-line growth and boosted its full-year outlook.

What's Behind Alexion's Impressive Q3 Results

Alexion Pharmaceuticals' (ALXN) CEO Ludwig Hantson on Q3 2020 Results - Earnings Call Transcript

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during its third quarter of fiscal 2020, which ended on Sept. 30.

Eaton Vance Exits Gilead, Alexion Pharmaceuticals

Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.

Alexion (ALXN) Beats on Q3 Earnings & Sales, Ups '20 Guidance

Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Alexion Pharmaceuticals (ALXN) Q3 Earnings and Revenues Surpass Estimates

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 6.7% in pre-market trading after the company reported Q3 results.

Alexion Pharmaceuticals: Q3 Earnings Insights

Alexion Pharmaceuticals earnings and revenue easily beat Q3 views. The biotech giant also raised full-year guidance, after saying it would.

News for Alexion Pharma Stock (ALXN)